Trial · NCT04382768
Inhaled Ibuprofen to Treat COVID-19
NCT04382768, Not applicable, Unknown, Química Luar SRL
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Ibuprofen to Treat COVID-19. Trials, record NCT04382768. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04382768
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Ibuprofen to Treat COVID-19
- NCT number
- NCT04382768
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Química Luar SRL
- Conditions
- Coronavirus Infection, Respiratory Disease, SARS (Disease)
- Interventions
- Inhaled Hypertonic ibuprofen
- First posted
- 2020-05-11
- Last updated
- 2020-06-11
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen. | 7, 14 and 28 days | Time to clinical improvement: defined as time from inhaled Ibuprofen first dose to an improvement of three points from the status on a seven-category ordinary scale |
| Primary | Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen. | 7, 14 and 28 days | Negativization of two consecutive pharyngo-nasal swab 24-72 hrs apart |
| Secondary | Chage in length of Hospital stay | 28 days | |
| Secondary | Chage in duration of ventilation | 28 days | |
| Secondary | Chage in length of Critical Care stay | 28 days | |
| Secondary | Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28. | 1, 7, 14 and 28 | NEWS2 score 20 points is the maximum and indicates that the patient needs emergent assessment by a clinical team or critical care team and usually transfer to higher level of care. |
| Secondary | Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28. | 1, 7, 14 and 28 days | qSOFA, score for sepsis, a maximum value of 3 indicates high risk qSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score. Patients meeting these qSOFA criteria should have infection considered even if it was previously not. |
| Secondary | Time from first dose to conversion to normal or mild pneumonia | 28 days | |
| Secondary | Antibiotic requirement | 28 days | |
| Secondary | Glucocorticoids requirement | 28 days |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04382768
GET https://conductscience.org/api/trials/v1/NCT04382768/registered